Experimental Topical Drug Shows Promise for AD, Psoriasis Experimental Topical Drug Shows Promise for AD, Psoriasis

In the phase 2 study, researchers at 34 sites in four countries randomized 104 patients with mild to moderate AD or psoriasis to receive the topical PDE4 inhibitor or a vehicle once daily for 6 weeks.MDedge News
Source: Medscape Allergy Headlines - Category: Allergy & Immunology Tags: Dermatology Source Type: news